Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine

The prospect of universal influenza vaccines is generating much interest and research at the intersection of immunology, epidemiology, and viral evolution. While the current focus is on developing a vaccine that elicits a broadly cross-reactive immune response in clinical trials, there are important downstream questions about global deployment of a universal influenza vaccine that should be explored to minimize unintended consequences and maximize benefits. Here, we review and synthesize the questions most relevant to predicting the population benefits of universal influenza vaccines and discuss how existing information could be mined to begin to address these questions. We review three research topics where computational modeling could bring valuable evidence: immune imprinting, viral evolution, and transmission. We address the positive and negative consequences of imprinting, in which early childhood exposure to influenza shapes and limits immune responses to future infections via memory of conserved influenza antigens. However, the mechanisms at play, their effectiveness, breadth of protection, and the ability to “reprogram” already imprinted individuals, remains heavily debated. We describe instances of rapid influenza evolution that illustrate the plasticity of the influenza virus in the face of drug pressure and discuss how novel vaccines could introduce new selective pressures on the evolution of the virus. We examine the possible unintended consequences of broadly protective (but infection-permissive) vaccines on the dynamics of epidemic and pandemic influenza, compared to conventional vaccines that have been shown to provide herd immunity benefits. In conclusion, computational modeling offers a valuable tool to anticipate the benefits of ambitious universal influenza vaccine programs, while balancing the risks from endemic influenza strains and unpredictable pandemic viruses. Moving forward, it will be important to mine the vast amount of data generated in clinical studies of universal influenza vaccines to ensure that the benefits and consequences of these vaccine programs have been carefully modeled and explored.

[1]  J. Gog,et al.  Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Cécile Viboud,et al.  Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. , 2005, The Journal of infectious diseases.

[3]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[4]  James O. Lloyd-Smith,et al.  Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting , 2016, Science.

[5]  T. Randall,et al.  A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.

[6]  Mark A. Miller,et al.  Influenza-Related Mortality Trends in Japanese and American Seniors: Evidence for the Indirect Mortality Benefits of Vaccinating Schoolchildren , 2011, PloS one.

[7]  Michael B. Doud,et al.  How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin , 2018, Nature Communications.

[8]  Caitlin E. Mullarkey,et al.  Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Mark A. Miller,et al.  Seasonal influenza in the United States, France, and Australia: transmission and prospects for control , 2007, Epidemiology and Infection.

[10]  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.

[11]  Patrick C. Wilson,et al.  Immune history profoundly affects broadly protective B cell responses to influenza , 2015, Science Translational Medicine.

[12]  S. Hensley,et al.  Immune history and influenza virus susceptibility. , 2017, Current opinion in virology.

[13]  Kimihito Ito,et al.  Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults , 2020, mBio.

[14]  D. Nokes,et al.  Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach , 2017, Vaccine.

[15]  Adolfo García-Sastre,et al.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.

[16]  A. Monto,et al.  Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States , 2018, The Journal of infectious diseases.

[17]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[18]  Jin Hyang Kim,et al.  Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains. , 2016, Vaccine.

[19]  P. Horby,et al.  Influenza Infection Rates, Measurement Errors and the Interpretation of Paired Serology , 2012, PLoS pathogens.

[20]  Mark A. Miller,et al.  The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. , 2007, Molecular biology and evolution.

[21]  Anne M Johnson,et al.  Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. , 2015, American journal of respiratory and critical care medicine.

[22]  Matthew S. Miller,et al.  Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic , 2018, mBio.

[23]  Katelyn M. Gostic,et al.  Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology. , 2017, Trends in microbiology.

[24]  A. Read,et al.  Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens , 2015, PLoS biology.

[25]  David J. Topham,et al.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.

[26]  C. M. Saad-Roy,et al.  Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza , 2020, Journal of the Royal Society Interface.

[27]  N. Arinaminpathy,et al.  Estimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States , 2017, American journal of epidemiology.

[28]  A. Flahault,et al.  Estimating the impact of school closure on influenza transmission from Sentinel data , 2008, Nature.

[29]  C. Viboud,et al.  First flu is forever , 2016, Science.

[30]  Esmeralda Alvarado-Facundo,et al.  Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it , 2019, PloS one.

[31]  C. Viboud,et al.  A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data , 2004, Statistics in medicine.

[32]  K. Subbarao,et al.  Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus , 2014, Clinical and Vaccine Immunology.

[33]  A S Perelson,et al.  Variable efficacy of repeated annual influenza vaccination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Peiris,et al.  Age-specific differences in the dynamics of protective immunity to influenza , 2018, Nature Communications.

[35]  δ-Antigen , 2019, Springer Reference Medizin.

[36]  Cecile Viboud,et al.  Impact of influenza vaccination on seasonal mortality in the US elderly population. , 2005, Archives of internal medicine.

[37]  J. Schulman EXPERIMENTAL TRANSMISSION OF INFLUENZA VIRUS INFECTION IN MICE , 1967, The Journal of experimental medicine.

[38]  W. John Edmunds,et al.  Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study , 2013, PLoS medicine.

[39]  Stephen S Morse,et al.  Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Diane J Post,et al.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases , 2018, The Journal of infectious diseases.

[41]  E. D. Kilbourne,et al.  Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.

[42]  Rong Hai,et al.  Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins , 2013, Proceedings of the National Academy of Sciences.

[43]  L. Simonsen,et al.  The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.

[44]  C. A. Russell,et al.  Antibody landscapes after influenza virus infection or vaccination , 2014, Science.

[45]  J. A. Misplon,et al.  Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen. , 2018, Vaccine.

[46]  B. Cowling,et al.  Sample Size Considerations for One-to-One Animal Transmission Studies of the Influenza A Viruses , 2013, PloS one.

[47]  P. Horby,et al.  Determinants of Influenza Transmission in South East Asia: Insights from a Household Cohort Study in Vietnam , 2014, PLoS pathogens.

[48]  J. Bloom,et al.  Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season , 2014, Proceedings of the National Academy of Sciences.

[49]  Cecile Viboud,et al.  Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza , 2012, Proceedings of the National Academy of Sciences.

[50]  A. Sant,et al.  Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus , 2019, Front. Immunol..

[51]  L. Simonsen,et al.  The virtues of antigenic sin: consequences of pandemic recycling on influenza-associated mortality , 2004 .

[52]  Benjamin J Cowling,et al.  Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  J. A. Misplon,et al.  Mucosal Immunization with a Candidate Universal Influenza Vaccine Reduces Virus Transmission in a Mouse Model , 2014, Journal of Virology.

[54]  Francisco A. Chaves,et al.  Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus , 2019, Journal of Virology.

[55]  Mark A. Miller,et al.  Transmission potential of influenza A/H7N9, February to May 2013, China , 2013, BMC Medicine.

[56]  Tao Dong,et al.  Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  Christopher S. Anderson,et al.  Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain , 2017, Scientific Reports.

[58]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[59]  Gavin J. D. Smith,et al.  Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China , 2012, PLoS pathogens.

[60]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[61]  F. Krammer Novel universal influenza virus vaccine approaches. , 2016, Current opinion in virology.

[62]  Christopher T. Stamper,et al.  Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial , 2019, The Lancet. Infectious diseases.

[63]  A. Hill,et al.  Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  Cécile Viboud,et al.  Searching for Sharp Drops in the Incidence of Pandemic A/H1N1 Influenza by Single Year of Age , 2012, PloS one.

[65]  A. Monto,et al.  Stochastic processes constrain the within and between host evolution of influenza virus , 2018, eLife.

[66]  D. Suarez,et al.  Influenza neuraminidase as a vaccine antigen. , 2009, Current topics in microbiology and immunology.

[67]  Mark M. Davis,et al.  Lineage Structure of the Human Antibody Repertoire in Response to Influenza Vaccination , 2013, Science Translational Medicine.

[68]  R. Lamb,et al.  Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice , 1990, Journal of virology.

[69]  Nimalan Arinaminpathy,et al.  Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines , 2016, PLoS Comput. Biol..

[70]  Katelyn M. Gostic,et al.  Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics , 2019, PLoS pathogens.

[71]  Strains , 2020, Encyclopedia of Continuum Mechanics.

[72]  D. Cummings,et al.  Timescales of influenza A/H3N2 antibody dynamics , 2017, bioRxiv.

[73]  A. Read,et al.  Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance , 2018, Proceedings of the National Academy of Sciences.

[74]  Benjamin J Cowling,et al.  Comparative epidemiology of pandemic and seasonal influenza A in households. , 2010, The New England journal of medicine.

[75]  L. Brammer,et al.  Birth Cohort Effects in Influenza Surveillance Data: Evidence that First Influenza Infection Affects Later Influenza-Associated Illness. , 2019, The Journal of infectious diseases.

[76]  A. Monto,et al.  Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. , 1970, The Journal of infectious diseases.

[77]  W. Barclay,et al.  Transmission of a 2009 H1N1 Pandemic Influenza Virus Occurs before Fever Is Detected, in the Ferret Model , 2012, PloS one.

[78]  Trevor Bedford,et al.  Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants , 2018, Proceedings of the National Academy of Sciences.

[79]  P. Wilson,et al.  The influenza virus hemagglutinin head evolves faster than the stalk domain , 2018, Scientific Reports.

[80]  P. Collins,et al.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.

[81]  Mark A. Miller,et al.  The origin and global emergence of adamantane resistant A/H3N2 influenza viruses , 2009, Virology.

[82]  T. Ben-Yedidia,et al.  Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. , 2014, Vaccine.

[83]  D. Earn,et al.  Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. , 2010, JAMA.

[84]  Ross Upshur,et al.  The Effect of Universal Influenza Immunization on Mortality and Health Care Use , 2008, PLoS medicine.

[85]  S. Epstein Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo. , 2018, American journal of epidemiology.

[86]  J. Peiris,et al.  Influenza A Virus Shedding and Infectivity in Households. , 2015, The Journal of infectious diseases.

[87]  R. Albrecht,et al.  A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies , 2017, npj Vaccines.

[88]  Michael G. Buhnerkempe,et al.  Mapping influenza transmission in the ferret model to transmission in humans , 2015, eLife.

[89]  J. Mascola,et al.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials , 2011, The Lancet Infectious Diseases.

[90]  W. C. Hwang,et al.  Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  M. Eichelberger,et al.  Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin , 2017, mBio.

[92]  R. Glover,et al.  Spread of Infection from the Respiratory Tract of the Ferret. I. Transmission of Influenza A Virus. , 1941 .

[93]  A. Kelso,et al.  Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity , 2015, mBio.

[94]  P. Wilson,et al.  Harnessing immune history to combat influenza viruses. , 2018, Current opinion in immunology.

[95]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[96]  R. Varadarajan,et al.  Stalking influenza by vaccination with pre-fusion headless HA mini-stem , 2016, Scientific Reports.

[97]  Raul Rabadan,et al.  Differences in Patient Age Distribution between Influenza A Subtypes , 2009, PloS one.

[98]  Thomas Francis,et al.  EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.

[99]  N. Cox,et al.  Global epidemiology of influenza: past and present. , 2000, Annual review of medicine.

[100]  C. M. Saad-Roy,et al.  Dynamic Perspectives on the Search for a Universal Influenza Vaccine. , 2019, The Journal of infectious diseases.

[101]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[102]  A. Monto,et al.  The Doctrine of Original Antigenic Sin: Separating Good From Evil , 2017, The Journal of infectious diseases.

[103]  Rahul Raman,et al.  Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift , 2009, Science.

[104]  S. de Lusignan,et al.  Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16. , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[105]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[106]  E. Belongia,et al.  Earliest infections predict the age distribution of seasonal influenza A cases , 2019, eLife.

[107]  J. Bloom,et al.  Parallel evolution of influenza across multiple spatiotemporal scales , 2017, eLife.

[108]  N. Ferguson,et al.  Ecological and immunological determinants of influenza evolution , 2003, Nature.

[109]  S. Epstein Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. , 2006, The Journal of infectious diseases.

[110]  A. Osterhaus,et al.  Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. , 2006, Vaccine.

[111]  Karlynn E. Neu,et al.  Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study , 2019, Journal of Virology.